We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Rides on New Products, Low Margin a Concern
Read MoreHide Full Article
On Aug 3, 2017, we issued an updated research report on San Diego, CA-based Illumina Inc. (ILMN - Free Report) , a company providing tools and integrated systems for the analysis of genetic variation and function.
Illumina exited the second quarter on a solid note, with both earnings and revenues beating the Zacks Consensus Estimate. The top line was strong with new product launches including the VeriSeq NIPT Solution in Europe and the strength of NovaSeq. More good news is that the rate of NIPT adoption is increasing outside the U.S.
Notably, over the last three months, Illumina has been trading above the broader industry. The stock has grown 4.8% in this period compared with a 3.9% gain of the broader industry. The company’s raised guidance is also encouraging enough to indicate that this bullish trend will continue in the coming period.
Also, demand for NovaSeq surpassed the company’s expectations with orders beating forecast over 30%. More than 230 NovaSeq instruments have been ordered since its launch in January. We are also looking forward to GRAIL, Illumina’s own-developed company, focused on the cancer screening market.
Within clinical markets, demand from customers undergoing oncology testing remains robust. We are currently looking forward to the performance of the Extended RAS Panel, slated for launch in the third quarter. Significantly in June, the company announced an FDA approval receipt for the Extended RAS companion diagnostic kit (as the Class III PMA).
On the flip side, weak margins owing to NovaSeq’s launch, higher array services revenues and product mix within sequencing consumables will continue to act as deterrents. Also, National Institutes of Health (NIH) funding issue and a tough competitive landscape are other few concerns to deal with.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 4.7% over the last three months.
INSYS Therapeutics has expected long-term earnings growth rate of 20%. The stock has gained around 4.7% over the last three months.
Align Technology has expected long-term adjusted earnings growth of almost 24.1%. The stock has surged roughly 24.7% over the last three months.
Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Illumina (ILMN) Rides on New Products, Low Margin a Concern
On Aug 3, 2017, we issued an updated research report on San Diego, CA-based Illumina Inc. (ILMN - Free Report) , a company providing tools and integrated systems for the analysis of genetic variation and function.
Illumina exited the second quarter on a solid note, with both earnings and revenues beating the Zacks Consensus Estimate. The top line was strong with new product launches including the VeriSeq NIPT Solution in Europe and the strength of NovaSeq. More good news is that the rate of NIPT adoption is increasing outside the U.S.
Notably, over the last three months, Illumina has been trading above the broader industry. The stock has grown 4.8% in this period compared with a 3.9% gain of the broader industry. The company’s raised guidance is also encouraging enough to indicate that this bullish trend will continue in the coming period.
Also, demand for NovaSeq surpassed the company’s expectations with orders beating forecast over 30%. More than 230 NovaSeq instruments have been ordered since its launch in January. We are also looking forward to GRAIL, Illumina’s own-developed company, focused on the cancer screening market.
Within clinical markets, demand from customers undergoing oncology testing remains robust. We are currently looking forward to the performance of the Extended RAS Panel, slated for launch in the third quarter. Significantly in June, the company announced an FDA approval receipt for the Extended RAS companion diagnostic kit (as the Class III PMA).
On the flip side, weak margins owing to NovaSeq’s launch, higher array services revenues and product mix within sequencing consumables will continue to act as deterrents. Also, National Institutes of Health (NIH) funding issue and a tough competitive landscape are other few concerns to deal with.
Zacks Rank & Key Picks
Illumina currently has a Zacks Rank #3 (Hold).
Some of the better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 4.7% over the last three months.
INSYS Therapeutics has expected long-term earnings growth rate of 20%. The stock has gained around 4.7% over the last three months.
Align Technology has expected long-term adjusted earnings growth of almost 24.1%. The stock has surged roughly 24.7% over the last three months.
Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>